Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autosomal Dominant Hypocalcemia Types 1 And 2 (ADH1/2) Disease Monitoring Study (DMS)

NCT05227287 is registered in ClinicalTrials.gov with Calcilytix Therapeutics, Inc., a BridgeBio company as lead sponsor.

NCT NCT05227287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05227287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autosomal Dominant Hypocalcemia Types 1 And 2 (ADH1/2) Disease Monitoring Study (DMS)
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase
Observational
Overall status
Active, not recruiting
Start date
January 20, 2022
Completion date
December 31, 2028
Enrollment
95 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant hypocalcemia